EC Clinical and Medical Case Reports

Review Article Volume 8 Issue 9 - 2025

Epigenetic Regulation of Neuroinflammation in Dementia of Alzheimer’s Disease and Other Forms of Dementias

Asem Surindro Singh1* and Machathoibi Takhellambam Chanu2*

1Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA

2Department of Biotechnology, Manipur University, Canchipur, Imphal West, Manipur, India

*Corresponding Author: Machathoibi Takhellambam Chanu, Department of Biotechnology, Manipur University, Canchipur, Imphal West, Manipur, India and Asem Surindro Singh, Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Received: July 22, 2025; Published: August 18, 2025



Over the years, research in Alzheimer’s disease (AD) continues to advance and enormous progress has been made towards understanding the pathology of AD. However, unavailability of an appropriate drug for treatment of AD raises several questions and scores the lack of thorough understanding of the regulatory mechanisms underlying the disease pathology. It signifies the need for further research to gain deeper understanding of the regulatory mechanisms underlying pathology of AD and uncover the hidden complexity of the disease. While most of the drugs that have been designed and proceeded to clinical trials are focused on clearing the aggregates of amyloid beta and the neurofibrillary tangles, the focus on neuroinflammatory pathways in causing neurodegeneration and dementia in AD is gradually emerging. Other pathological pathways that have profound regulatory functions underlying AD dementia include transportation and metabolism of APOE mediated cholesterol, TREM2 mutation, DNA methylation, histone modification and non-coding RNAs etc. Even though there is progress in this area of research, we believe that further strengthening is necessary highlighting their substantial roles in the pathogenesis of the disease. Over the years, several research have also indicated the involvement of epigenetic mechanisms in the developing memory formation in pathological or physiological conditions of the diseases. This review is particularly focused to highlight the epigenetic regulation of APOE, TREM2, DNA methylation, histone modification and non-coding RNAs that contribute to neuroinflammation leading to dementia of AD and related cognitive impairments.

 Keywords: Alzheimer’s Disease; Dementia; Neuroinflammation; TREM2; APOE4; DNA Methylation; Histone Modification; Non-Coding RNAs

  1. World Health Organisation (WHO). “The top 10 causes of death” (2024).
  2. “2024 Alzheimer's disease facts and figures”. Alzheimer's and Dementia 5 (2024): 3708-3821.
  3. Rajan KB., et al. “Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060)”. Alzheimer's and Dementia 12 (2021): 1966-1975.
  4. Singh AS., et al. “Neuroinflammation and progress in clinical trials for the treatment of Alzheimer’s disease and related dementias: An update”. Innovative Medicines and Omics2 (2025): 36-50.
  5. Friedman EM., et al. “US Prevalence and predictors of informal caregiving for dementia”. Health Affairs (Millwood)10 (2015): 1637-1641.
  6. Tatulian SA. “Challenges and hopes for Alzheimer's disease”. Drug Discovery Today 4 (2022): 1027-1043.
  7. Frozza RL., et al. “Challenges for Alzheimer's disease therapy: Insights from novel mechanisms beyond memory defects”. Frontiers in Neuroscience 12 (2018): 37.
  8. Singh AS and Chanu MT. “Alzheimer’s disease and Aβ pathways”. World Journal of Advanced Research and Reviews 12 (2021): 542-544.
  9. Lecca D., et al. “Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis”. Alzheimer's and Dementia 11 (2022): 2327-2340.
  10. Sobue A., et al. “Neuroinflammation in Alzheimer's disease: microglial signature and their relevance to disease”. Inflammation and Regeneration 1 (2023): 26.
  11. Noyes K and Weinstock-Guttman B. “Impact of diagnosis and early treatment on the course of multiple sclerosis”. American Journal of Managed Care 17 (2013): s321-s331.
  12. Cignarella F., et al. “TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis”. Acta Neuropathologica 4 (2020): 513-534.
  13. Price BR., et al. “Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition”. Journal of Neuroinflammation 1 (2020): 238.
  14. Lock C., et al. “Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis”. Nature Medicine 5 (2002): 500-508.
  15. West PK., et al. “The cytokines interleukin-6 and interferon-alpha induce distinct microglia phenotypes”. Journal of Neuroinflammation 1 (2022): 96.
  16. Calabresi PA. “Diagnosis and management of multiple sclerosis”. American Family Physician 10 (2004): 1935-1944.
  17. Chiaravalloti ND and DeLuca J. “Cognitive impairment in multiple sclerosis”. Lancet Neurology 12 (2008): 1139-1151.
  18. McQuade A., et al. “Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer's disease”. Nature Communications 1 (2020): 5370.
  19. Fassler M., et al. “Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer's disease models”. Journal of Neuroinflammation 18 (2021): 19.
  20. Wang S., et al. “Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model”. Journal of Experimental Medicine 9 (2020): e20200785.
  21. Ozaki Y., et al. “DNA methylation changes at TREM2 intron 1 and TREM2 mRNA expression in patients with Alzheimer's disease”. Journal of Psychiatric Research 92 (2017): 74-80.
  22. Lu Y., et al. “Regulation of TREM2 expression by transcription factor YY1 and its protective effect against Alzheimer's disease”. Journal of Biological Chemistry 5 (2023): 104688.
  23. Mahley RW. “Apolipoprotein E: cholesterol transport protein with expanding role in cell biology”. Science4852 (1988): 622-630.
  24. Poirier J., et al. “Apolipoprotein E polymorphism and Alzheimer's disease”. Lancet8873 (1993): 697-699.
  25. Corder EH., et al. “Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families”. Science 5123 (1993): 921-923.
  26. DeMattos RB., et al. “ApoE and cluster in cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo”. Neuron 2 (2004): 193-202.
  27. Wang SC., et al. “Age-specific epigenetic drift in late-onset alzheimer's disease”. PLoS One7 (2008): e2698.
  28. Foraker J., et al. “The APOE gene is differentially methylated in Alzheimer's disease”. Journal of Alzheimer's Disease 3 (2015): 745-755.
  29. Huebbe P and Rimbach G. “Evolution of human apolipoprotein E (APOE) isoforms: Gene structure, protein function and interaction with dietary factors”. Ageing Research Reviews 37 (2017): 146-161.
  30. Finch CE and Stanford CB. “Meat-adaptive genes and the evolution of slower aging in humans”. Quarterly Review of Biology 1 (2004): 3-50.
  31. Yu CE and Foraker J. “Epigenetic considerations of the APOE gene”. BioMolecular Concepts 1 (2015): 77-84.
  32. Gibbs JR., et al. “Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain”. PLOS Genetics 5 (2010): e1000952.
  33. Holliday R. “Epigenetics: an overview”. Developmental Genetics 6 (1994): 453-457.
  34. Sananbenesi F and Fischer A. “The epigenetic bottleneck of neurodegenerative and psychiatric diseases”. Biological Chemistry11 (2009): 1145-1153.
  35. Stilling RM and Fischer A. “The role of histone acetylation in age-associated memory impairment and Alzheimer's disease”. Neurobiology of Learning and Memory 1 (2011): 19-26.
  36. Oliveira AM., et al. “Rescue of aging-associated decline in Dnmt3a2 expression restores cognitive abilities”. Nature Neuroscience 8 (2012): 1111-1113.
  37. Jones PA. “Functions of DNA methylation: islands, start sites, gene bodies and beyond”. Nature Reviews Genetics 7 (2012): 484-492.
  38. Di Francesco A., et al. “Global changes in DNA methylation in Alzheimer's disease peripheral blood mononuclear cells”. Brain, Behavior, and Immunity 45 (2015): 139-144.
  39. Schroder H., et al. “Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease”. Neurobiology of Aging 3 (1991): 259-262.
  40. Bekdash RA. “Choline, the brain and neurodegeneration: insights from epigenetics”. Frontiers in Bioscience (Landmark Edition)6 (2018): 1113-1143.
  41. Nicolia V., et al. “DNA methylation profiles of selected pro-inflammatory cytokines in Alzheimer disease”. Journal of Neuropathology and Experimental Neurology 1 (2017): 27-31.
  42. Nagata T., et al. “Association between DNA Methylation of the BDNF Promoter Region and Clinical Presentation in Alzheimer's Disease”. Dementia and Geriatric Cognitive Disorders Extra 1 (2015): 64-73.
  43. Cui XL., et al. “A human tissue map of 5-hydroxymethylcytosines exhibits tissue specificity through gene and enhancer modulation”. Nature Communications 1 (2020): 6161.
  44. Condliffe D., et al. “Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain”. Neurobiology of Aging 8 (2014): 1850-1854.
  45. Bradley-Whitman MA and Lovell MA. “Epigenetic changes in the progression of Alzheimer's disease”. Mechanisms of Ageing and Development 10 (2013): 486-495.
  46. Celarain N., et al. “TREM2 upregulation correlates with 5-hydroxymethycytosine enrichment in Alzheimer's disease hippocampus”. Clinical Epigenetics 8 (2016): 37.
  47. Coppieters N., et al. “Global changes in DNA methylation and hydroxymethylation in Alzheimer's disease human brain”. Neurobiology of Aging 6 (2014): 1334-1344.
  48. Lee EG., et al. “Redefining transcriptional regulation of the APOE gene and its association with Alzheimer's disease”. PLoS One 1 (2020): e0227667.
  49. Tulloch J., et al. “Glia-specific APOE epigenetic changes in the Alzheimer's disease brain”. Brain Research 1698 (2018): 179-186.
  50. Globisch D., et al. “Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates”. PLoS One12 (2010): e15367.
  51. Szulwach KE., et al. “5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging”. Nature Neuroscience 12 (2011): 1607-1616.
  52. Wang F., et al. “Genome-wide loss of 5-hmC is a novel epigenetic feature of Huntington's disease”. Human Molecular Genetics 18 (2013): 3641-3653.
  53. Wang T., et al. “Genome-wide DNA hydroxymethylation changes are associated with neurodevelopmental genes in the developing human cerebellum”. Human Molecular Genetics 26 (2012): 5500-5510.
  54. Fass DM., et al. “Epigenetic mechanisms in mood disorders: targeting neuroplasticity”. Neuroscience 264 (2014): 112-130.
  55. Mbadiwe T and Millis RM. “Epigenetics and autism”. Autism Research and Treatment (2013): 826156.
  56. Matsumoto L., et al. “CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease”. PLoS One 11 (2010): e15522.
  57. Zusso M., et al. “Neuroepigenetics and Alzheimer's disease: An update”. Journal of Alzheimer's Disease 3 (2018): 671-688.
  58. Wang T., et al. “Epigenetic basis of lead-induced neurological disorders”. International Journal of Environmental Research and Public Health 13 (2020): 4878.
  59. Surace AEA and Hedrich CM. “The role of epigenetics in autoimmune/inflammatory disease”. Frontiers in Immunology 10 (2019): 1525.
  60. Fischer A., et al. “Recovery of learning and memory is associated with chromatin remodelling”. Nature7141 (2007): 178-182.
  61. Herre M and Korb E. “The chromatin landscape of neuronal plasticity”. Current Opinion in Neurobiology 59 (2019): 79-86.
  62. Levenson JM., et al. “Regulation of histone acetylation during memory formation in the hippocampus”. Journal of Biological Chemistry 39 (2004): 40545-40559.
  63. Alarcon JM., et al. “Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration”. Neuron6 (2004): 947-959.
  64. Lubin FD., et al. “Epigenetic regulation of BDNF gene transcription in the consolidation of fear memory”. Journal of Neuroscience 42 (2008): 10576-10586.
  65. Bredy TW., et al. “Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear”. Learning and Memory 4 (2007): 268-276.
  66. Su Q., et al. “Trichostatin A ameliorates Alzheimer's disease-related pathology and cognitive deficits by increasing albumin expression and Abeta clearance in APP/PS1 mice”. Alzheimer's Research and Therapy 1 (2021): 7.
  67. Wood IC. “The contribution and therapeutic potential of epigenetic modifications in Alzheimer's disease”. Frontiers in Neuroscience 12 (2018): 649.
  68. Nativio R., et al. “An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer's disease”. Nature Genetics 10 (2020): 1024-1035.
  69. Rao JS., et al. “Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients”. Translational Psychiatry 7 (2012): e132.
  70. Dokmanovic M., et al. “Histone deacetylase inhibitors: overview and perspectives”. Molecular Cancer Research 10 (2007): 981-989.
  71. Gjoneska E., et al. “Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease”. Nature7539 (2015): 365-369.
  72. Govindarajan N., et al. “Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease”. EMBO Molecular Medicine 1 (2013): 52-63.
  73. Leyk J., et al. “Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance”. Journal of Molecular Neuroscience 4 (2015): 1031-1046.
  74. Chaput D., et al. “Potential role of PCTAIRE-2, PCTAIRE-3 and P-Histone H4 in amyloid precursor protein-dependent Alzheimer pathology”. Oncotarget8 (2016): 8481-8497.
  75. Anderson KW and Turko IV. “Histone post-translational modifications in frontal cortex from human donors with Alzheimer's disease”. Clinical Proteomics 12 (2015): 26.
  76. Gong B., et al. “The Ubiquitin-Proteasome System: Potential Therapeutic Targets for Alzheimer's Disease and Spinal Cord Injury”. Frontiers in Molecular Neuroscience 9 (2016): 4.
  77. David G., et al. “SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities”. Journal of Biological Chemistry 26 (2002): 23658-23663.
  78. Tao CC., et al. “Epigenetic regulation of HDAC1 SUMOylation as an endogenous neuroprotection against Abeta toxicity in a mouse model of Alzheimer's disease”. Cell Death and Differentiation 4 (2017): 597-614.
  79. Kurt S., et al. “Altered Expression of Long Non-coding RNAs in Peripheral Blood Mononuclear Cells of Patients with Alzheimer's Disease”. Molecular Neurobiology 12 (2020): 5352-5361.
  80. Zhang Y., et al. “The Role of Non-coding RNAs in Alzheimer's Disease: From Regulated Mechanism to Therapeutic Targets and Diagnostic Biomarkers”. Frontiers in Aging Neuroscience 13 (2021): 654978.
  81. Tian N., et al. “MiR-206 decreases brain-derived neurotrophic factor levels in a transgenic mouse model of Alzheimer's disease”. Neuroscience Bulletin 2 (2014): 191-197.
  82. Lima Giacobbo B., et al. “Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation”. Molecular Neurobiology 5 (2019): 3295-3312.
  83. Beeri MS and Sonnen J. “Brain BDNF expression as a biomarker for cognitive reserve against Alzheimer disease progression”. Neurology8 (2016): 702-703.
  84. Somkuwar SS., et al. “Alcohol dependence-induced regulation of the proliferation and survival of adult brain progenitors is associated with altered BDNF-TrkB signaling”. Brain Structure and Function 9 (2016): 4319-4335.
  85. Rosa JM., et al. “Prophylactic effect of physical exercise on Abeta(1-40)-induced depressive-like behavior: Role of BDNF, mTOR signaling, cell proliferation and survival in the hippocampus”. Progress in Neuropsychopharmacology and Biological Psychiatry 94 (2019): 109646.
  86. Li W., et al. “MicroRNA-613 regulates the expression of brain-derived neurotrophic factor in Alzheimer's disease”. BioScience Trends 5 (2016): 372-377.
  87. Idda ML., et al. “Noncoding RNAs in Alzheimer's disease”. Wiley Interdisciplinary Reviews: RNA 2 (2018): 10.
  88. Hombach S and Kretz M. “Non-coding RNAs: Classification, Biology and Functioning”. Advances in Experimental Medicine and Biology 937 (2016): 3-17.
  89. Chen X., et al. “Level of LncRNA GAS5 and Hippocampal Volume are Associated with the Progression of Alzheimer's Disease”. Clinical Interventions in Aging 17 (2022): 745-753.
  90. Feng L., et al. “Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease”. BMC Neurology1 (2018): 4.
  91. Shobeiri P., et al. “Circulating long non-coding RNAs as novel diagnostic biomarkers for Alzheimer's disease (AD): A systematic review and meta-analysis”. PLoS One3 (2023): e0281784.
  92. Ma P., et al. “Long non-coding RNA MALAT1 inhibits neuron apoptosis and neuroinflammation while stimulates neurite outgrowth and its correlation with MiR-125b Mediates PTGS2, CDK5 and FOXQ1 in Alzheimer's Disease”. Current Alzheimer Research 7 (2019): 596-612.
  93. World Health Organisation. “Dementia: Key facts” (2024).
  94. Huang LK., et al. “Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update”. Journal of Biomedical Science 1 (2023): 83.
  95. Liu P., et al. “Neuroinflammation as a potential therapeutic target in Alzheimer's disease”. Clinical Interventions in Aging 17 (2022): 665-674.
  96. Agarwal D., et al. “Crosstalk between epigenetics and mTOR as a gateway to new insights in pathophysiology and treatment of Alzheimer's disease”. International Journal of Biological Macromolecules 192 (2021): 895-903.
  97. Cosin-Tomas M., et al. “Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations”. Molecular Neurobiology 7 (2017): 5550-5562.
  98. Lunnon K and Mill J. “Epigenetic studies in Alzheimer's disease: current findings, caveats, and considerations for future studies”. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 8 (2013): 789-799.
  99. Singh M., et al. “Circular RNA ciRS-7 signature as a potential biomarker for the early detection of diabetes with Alzheimer's disease: a hypothesis”. Molecular Biology Reports 10 (2023): 8705-8714.

Asem Surindro Singh and Machathoibi Takhellambam Chanu. “Epigenetic Regulation of Neuroinflammation in Dementia of Alzheimer’s Disease and Other Forms of Dementias”. EC Clinical and Medical Case Reports  8.9 (2025): 01-14.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net